ARCHIVES

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Grant Funding: “Zone of Likelihood” Moves From 7th to 9th Percentile

November 30, 2012

Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer

November 27, 2009

Trials Approved by NCI CTEP For The Month of February

February 24, 2012

ONS Annual Meeting To Highlight Nursing Progress In ‘70s, ‘80s

April 20, 1990

Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival

August 31, 2012

RRP Planning Dosimetry Center, Treatment Planning Projects

March 20, 1987